Occasionally the dangers associated with taking a drug far outweigh the ailment that initially called for it to be prescribed. Drug-makers Merck, Bristol-Myers Squibb and Novo Nordisk, major manufacturers of diabetes drugs, are now being scrutinized for their reported link to pancreatic cancer.
The FDA is now launching an investigation into the side effects these drugs produce. The agency has already received a high number of reports indicating that users of these specialized drugs developed pancreatic cancer, devastating consequences for those simply trying to maintain quality of life amidst diabetes.
The problem with many bad drugs is the side effects are not readily apparent. Regardless of a company advertising the consequences or not, the harsh penalties associated with these drugs sometimes aren’t displayed for years. Trying to prevent the fatal consequences is a delicate process that requires fast legal proceedings and community awareness.
The FDA, deeming the diabetic drug complaints have reached a critical level, will now be investigating the unpublished findings from these major manufacturers. The FDA investigation will likely take a significant length of time, but the outcome could result a hefty bill to the manufacturers for significant damages stemming from a large list of complaints.